Background: Most patients with juvenile myelomonocytic leukemia (JMML) are curable only with allogeneic hematopoietic cell transplantation (HCT). However, the current standard conditioning regimen, busulfan-cyclophosphamide-melphalan (Bu-Cy-Mel), may be associated with higher risks of morbidity and mortality. ASCT1221 was designed to test whether the potentially lesstoxic myeloablative conditioning regimen containing busulfan-fludarabine (Bu-Flu) would be associated with equivalent outcomes. Procedure: Twenty-seven patients were enrolled on ASCT1221 from 2013 to 2015. Pre-and post-HCT (starting Day +30) mutant allele burden was measured in all and pre-HCT therapy was administered according to physician discretion.
METHODS

Eligibility
(FISH) analysis for monosomy 7) , and molecular testing was performed to ensure that patients met consensus criteria for JMML 10 prior to proceeding to HCT on Part 2 of the study. Patients with germline mutations in PTPN11 or who had progressed to AML (>20% blasts) were excluded.
Pre-HCT therapy
ASCT1221 did not mandate the use of, or a particular approach to, pre-HCT therapy (including the potential use of splenectomy), which was left to the discretion of the treating physician. The use of pre-HCT chemotherapy was captured and defined as none, low-dose (including treatment with 6-mercaptopurine and/or cis-retinoic acid), or AML-like (cytarabine ≥1 g/m 2 /day ± other agents).
Conditioning and transplant
All patients who met eligibility criteria (appropriate donor identified, adequate organ function, absence of uncontrolled infection) could proceed to HCT per the treating physician. Donor selection was per treating physician and included matched siblings (MSD), adult unrelated donors (URD), and umbilical cord blood (UCB), but not haploidentical-related donors. Allele-level HLA-matching at ≥7/8 loci was required for URD. For UCB, ≥4/6 serologic HLA-matching at HLA-A and HLA-B (with allele level at HLA-DR), and a dose ≥5 × 10 7 nucleated cells per kg were required. Stratified randomization occurred based on donor type and the presence of PTNP11 mutations, which have been considered high risk. [11] [12] [13] Conditioning regimen A (Bu-Cy-Mel) was intravenous busulfan (initial 3.2-4 mg/kg/day, with 1-2 therapeutic dose adjustments to for URD/UCB), and mycophenolate mofetil (15 mg/kg/dose every 8 hr;
from Day +1 to Day +30 for MSD, or Day +45 for URD/UCB).
Response criteria and definitions
Disease response was defined according to the international consensus criteria.{Niemeyer, 2015 #1806} 14 Mutant allele burden was measured at diagnosis, prior to HCT and at regular intervals after HCT, with the first measurement occurring at Day +30. Primary graft failure was defined as failure to achieve an absolute neutrophil count of ≥500/mm 3 after 42 days or < 5% donor cells in bone marrow by Day +42, without evidence of JMML. SOS was defined by the Baltimore criteria. 15 Grade 3/4 toxicities were collected using CTCAEv4.0. Acute (aGVHD) and chronic GVHD were scored using consensus criteria. 16, 17 For the purpose of this analysis, clinical high-risk disease at diagnosis was defined as being >2 years of age, 11, 13, 18 platelets <40 × 10 9 /l, 18 or having a hemoglobin F elevated for age. 1, 18 Biologic high-risk disease was defined as having any cytogenetic abnormality, 2,13 secondary mutations, 19 All patients enrolled on ASCT1221 were sequenced to determine their JMML mutation status in real time using a CLIA-certified assay at diagnosis, pre-HCT, at defined time points post-HCT, and at relapse (when applicable). The entire coding sequence of Ras-pathway genes including NF1, NRAS, KRAS, PTPN11, and CBL were analyzed and the allele fraction of each mutation was reported to the treating physician. All patients were analyzed on the Ion-Torrent platform using a tumor-normal approach to distinguish germline from somatic mutations, as described previously. 21 Tumor samples were obtained from mononuclear cells from blood or bone marrow. Germline samples were obtained from buccal swabs or bone marrow fibroblasts. 
Exome sequencing
Three of 15 transplanted patients who had relapse samples available were analyzed using whole exome sequencing (WES) with a trio approach (normal diagnosis relapse). Analysis and determination of pathogenic variants and copy number were performed, as previously described. 21,22
DNA methylation analysis
Fourteen of 15 transplanted patients had diagnostic tumor DNA available for genome-wide DNA methylation analysis performed using the Illumina 450k BeadChip platform. Patient samples from ASCT1221
were compared to a cohort of 39 distinct patients with JMML, and using a "nearest centroid neighbor" approach were classified with a low, intermediate, or high methylation-cluster designation, as previously described. 20
Statistical analysis
ASCT1221 was powered to accrue 54 patients in each arm in order to pick the winner of regimens, Arm A and Arm B in terms of TRM and EFS, with the outcome determined after all eligible patients had ≥18 months of follow-up, as patients with JMML rarely relapse >18 months post-HCT. 1,2 An interim analysis of outcomes at 2 years after the start of the study was planned to look at rates of graft failure, relapse, and TRM. Primary response measures were TRM, EFS, overall survival (OS), and relapse/disease progression as of June 30, 2017.
The Kaplan-Meier method was used to estimate probabilities of EFS and OS. Events were defined as relapse/progression or TRM. The probabilities of relapse/progression, TRM, SOS, and GVHD were estimated using the method of cumulative incidence that accounts for competing events (i.e., death). The significance of observed differences in proportions was tested using Fisher's exact test. Clopper-Pearson was used to calculate confidence intervals. Comparison of median between arms was done using Wilcoxon rank-sum test. All tests were two-sided with P values <0.05 considered statistically significant.
RESULTS
Patient characteristics
Thirty patients were enrolled, however three patients were determined to not meet diagnostic criteria for JMML (Supplementary Figure S1) . The baseline characteristics of the remaining 27 patients are listed in were intentionally observed without HCT per physician preference, all without signs of progression at the last follow-up. Four patients were treated with nonprotocol HCT, three after randomization was suspended.
Baseline characteristics between Arm A (Bu-Cy-Mel) and Arm B (Bu-Flu) were notable for 33% (2/6) of patients in Arm A retrospectively identified to have high-risk biological features compared to 67% (6/9) of patients in Arm B (P = 0.31). In the 15 randomized patients, mutant allele burden was measured at the time of diagnosis and within 2 weeks of the start of conditioning. As shown in Figure 1 , the use of low-dose pre-HCT chemotherapy did not impact mutant allele burden compared to no chemotherapy, however, the two patients given AMLlike chemotherapy achieved low mutant allele burdens (0% and 1.4%) upon count recovery. No patient underwent splenectomy prior to HCT.
HCT toxicities and GVHD
Cumulative busulfan exposure was similar between the 2 arms 
Disease progression post-HCT
All patients had evidence of primary neutrophil recovery. One patient in Arm B had secondary graft loss (no detectable donor chimerism)
in conjunction with JMML progression. For the other 13 patients, the median initial whole blood chimerism was 100% (range, 98-100%)
TA B L E 1 Clinical and molecular characteristics at the time of diagnosis for eligible patients
Total enrolled 27
Male sex 17 (63%) for patients in Arm A, compared to 97% (range, 51-100%) in Arm B (P = 0.03). Patient-level risk characteristics and outcomes are shown in Table 3 . The cumulative incidence of disease progression by 18 months was 17% (95% CI, 0.4-55%) and 55% (95% CI, 16-83%) for patients on Arms A and B, respectively (P = 0.19).
Two general patterns of disease progression were noted (Figure 2 ).
Two patients (both in Arm B) entered HCT with large disease burdens (clinically and molecularly). Although both recovered neutrophils (and one had Grade III aGVHD), they also continued to have clinical and molecular signs of residual JMML and were scored as nonresponders.
Two patients (both in Arm B) appeared to be in clinical remission post-HCT, however, they continued to have low mutant allele burden (0.8- at diagnosis, implying that clonal evolution contributed to relapse in these patients.
Post-HCT survival
The estimated 18-month post-HCT EFS of the entire cohort was 47%
(95% CI, 21-69%), with a median follow-up time of 29 months (range, 13-44 months) in surviving patients. As shown in Figure 3 , the estimated 18-month EFS was 83% (95% CI, 27-97%) and 22% (95% CI, 03-51%) in Arms A and B, respectively (P = 0.04). When this imbalance in events became apparent, the Data and Safety Monitoring Committee suspended further randomization and ASCT1221 was closed.
Patients who relapsed/progressed post-HCT were taken off-study and treated per physician discretion. The estimated 18-month post-HCT OS was 64% (95% CI, 34-83%) overall, with 83% (95% CI, 27-97%) and 48% (95% CI, 12-77%) in Arms A and B, respectively (P = 0.26).
Patients with biological high-risk disease (classified retrospectively)
had a similar 18-month EFS compared to standard-risk disease: 50%
(95% CI, 15-77%) and 43% (95% CI, 10-73%), respectively (P = 0.41), though small numbers limits ASCT1221's power to address this question. The 18-month EFS was 17% (95% CI, 0.77-52%) in patients not treated with any chemotherapy, 57% (17-84%) in patients who were given low-dose chemotherapy, and 100% in the two patients treated with AML-like chemotherapy (P = 0.08). Conclusions regarding the optimal conditioning regimen are limited by small numbers, possible imbalances in disease severity between the arms, and differing approaches to pre-HCT chemotherapy; the latter two potentially having a substantial impact on post-HCT outcomes.
DISCUSSION
Nevertheless, ASCT1221 is the first prospective trial wherein all transplanted patients were molecularly characterized and confirmed to have JMML, an important consideration given that there are known mimics of the disease, such as Wiskott-Aldrich Syndrome 23 and Infantile Osteopetrosis. 24 In regards to disease severity, to date a consensus risk-stratification system for patients with JMML is lacking. Treating physicians were allowed to choose whether to administer any pre-HCT chemotherapy, therefore patients presented to in patients who received AML-like therapy compared to none or lowdose chemotherapy (55% vs. 32%; P = 0.048). 2 COG AAML0122 evaluated the efficacy of a pretransplant window therapy with a farnesyl transferase inhibitor followed by two cycles of intensive AMLtype chemotherapy using fludarabine and cytarabine. 30 For patients who achieved a complete response (defined as normalization of white blood cell (WBC) count and resolution of organomegaly) there was a trend toward improved 5-year EFS (54% vs. 33%, P = 0.144) and 5-year relapse rate (38% vs. 57%, P = 0.154), though AAML0122 was not powered to address this question. The Japanese Pediatric MDS Study Group's JMML HCT report included three patients who received AML-like chemotherapy prior to HCT; all remained relapse-free. 7 
